Literature DB >> 10684587

A new functional classification of tumor-suppressing genes and its therapeutic implications.

M Q Islam1, K Islam.   

Abstract

Cell fusion studies have demonstrated that malignancy can be suppressed by a single dose of malignancy suppressor genes (MSGs), indicating that malignancy is a recessive phenotype. Correspondingly, it is widely believed that mutational inactivation of both alleles of tumor suppressor genes (TSGs), in familial and sporadic tumors, is the formal proof of the recessive nature of malignancy. Evidence presented here, however, shows that unlike MSGs, identified solely through cell fusion studies with no gene of this class yet cloned, many well-known TSGs have gene dosage effects and inhibit cellular growth in vitro. Moreover, homozygous inactivation of a growth-inhibitory TSG (GITSG) is not directly correlated with malignancy. An alternative interpretation is provided for the loss of wild-type alleles of these genes in the tumors. It is concluded that the MSGs and the GITSGs do not belong to the same class of genes. The functional classification of tumor-suppressing genes has important implications for developing effective cancer therapies. Copyright 2000 John Wiley & Sons, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10684587     DOI: 10.1002/(SICI)1521-1878(200003)22:3<274::AID-BIES9>3.0.CO;2-G

Source DB:  PubMed          Journal:  Bioessays        ISSN: 0265-9247            Impact factor:   4.345


  5 in total

1.  Dido gene expression alterations are implicated in the induction of hematological myeloid neoplasms.

Authors:  Agnes Fütterer; Miguel R Campanero; Esther Leonardo; Luis M Criado; Juana M Flores; Jesús M Hernández; Jesús F San Miguel; Carlos Martínez-A
Journal:  J Clin Invest       Date:  2005-08-25       Impact factor: 14.808

2.  Epigenetic Silencing of ALDH1L1, a Metabolic Regulator of Cellular Proliferation, in Cancers.

Authors:  Natalia V Oleinik; Natalia I Krupenko; Sergey A Krupenko
Journal:  Genes Cancer       Date:  2011-02

3.  Clinical significance of loss of heterozygosity for M6P/IGF2R in patients with primary hepatocellular carcinoma.

Authors:  Hong Seok Jang; Ki Mun Kang; Byung Ock Choi; Gyu Young Chai; Soon Chan Hong; Woo Song Ha; Randy L Jirtle
Journal:  World J Gastroenterol       Date:  2008-03-07       Impact factor: 5.742

4.  M6P/IGF2R loss of heterozygosity in head and neck cancer associated with poor patient prognosis.

Authors:  Timothy A Jamieson; David M Brizel; J Keith Killian; Yoshihiko Oka; Hong-Seok Jang; Xiaolong Fu; Robert W Clough; Robin T Vollmer; Mitchell S Anscher; Randy L Jirtle
Journal:  BMC Cancer       Date:  2003-02-13       Impact factor: 4.430

5.  Current awareness on comparative and functional genomics.

Authors: 
Journal:  Yeast       Date:  2000-09-30       Impact factor: 3.239

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.